In this episode of the Eye on AI podcast, we explore the cutting-edge intersection of AI and biotechnology with Raphael Townshend, founder and CEO of Atomic AI. Raphael delves into the revolutionary potential of AI in RNA drug discovery, highlighting Atomic AI's innovative approach. He shares his journey from studying electrical engineering and computer science at UC Berkeley to developing advanced AI models for understanding RNA structures, analogous to DeepMind's AlphaFold for proteins. We dive deep into the intricacies of RNA's role in the human genome and its untapped potential in treating diseases previously considered undruggable. Raphael explains how Atomic AI's core model, Atom 1, is designed to predict RNA shapes with unprecedented accuracy, enabling the design of new drugs that target RNA instead of proteins. He discusses the significance of RNA in the context of mRNA vaccines, particularly the COVID-19 vaccine, and the challenges of making these vaccines more stable and accessible. The conversation also covers the technical aspects of using AI, including transformer-based models and in-house data generation, to enhance RNA drug discovery. Raphael shares insights into the company's progress, from cell testing to upcoming animal trials, and the broader implications of integrating AI in biotechnology. Join us as we uncover the future of RNA-based therapies, the innovative use of AI in drug discovery, and the groundbreaking advancements that could transform the landscape of medicine. Don't forget to like, subscribe, and hit the notification bell for more expert insights into the latest AI innovations. This episode is sponsored by SysAid, the Next-gen ITSM Platform. Get 20% off SysAid Copilot using this link: https://www.sysaid.com/lp/sysaid-copilot-s?utm_source=youtube&utm_medium=cpc&utm_campaign=short-craig Stay Updated: Craig Smith Twitter: https://twitter.com/craigss Eye on A.I. Twitter: https://twitter.com/EyeOn_AI

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.